Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Andrew Sassine
AddedFeb 15, 2024
UpdatedMay 31, 2026
Andrew Sassine

Andrew Sassine

Board Member, Arcturus Therapeutics Holdings

CrunchbaseLinkedInThe Org

Andrew Sassine's Career

Arcturus Therapeutics Holdings
Arcturus Therapeutics Holdings

San Diego, CA, US

Board Member· Board
Icad
Icad

Nashua, NH, US

Board Member· Board
Freedom Meditech
Freedom Meditech

San Diego, CA, US

Board Member· Board
Comhear
Comhear

San Diego, CA, US

Board Member· Board
MD Revolution
MD Revolution

Solana Beach, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Andrew Sassine's Career

Arcturus Therapeutics Holdings
Arcturus Therapeutics Holdings
Public1702019San Diego, CA, US
Board Member· Board

Leadership at Arcturus Therapeutics Holdings

Padmanabh ChivukulaPadmanabh ChivukulaCo-Founder
Joseph PayneJoseph PayneCo-Founder
Jing MarantzJing MarantzBoard Member
Magda MarquetMagda MarquetBoard Member
Peter FarrellPeter FarrellBoard Member
Edward W. HolmesEdward W. HolmesBoard Member

Similar to Arcturus Therapeutics Holdings

Orbital TherapeuticsOrbital TherapeuticsCambridge, MA, USMedicines, RNA Therapiesest. 2022Orbital TherapeuticsCambridge, MA, US · est. 2022

Orbital Therapeutics: Advancing global health with innovative RNA-based medicines.

Series A · $270M33
Sirius TherapeuticsSirius TherapeuticsSan Diego, CA, USRnai Therapiesest. 2021Sirius TherapeuticsSan Diego, CA, US · est. 2021

San Diego-based Sirius Therapeutics innovates RNAi therapies for cardiovascular diseases.

Series B · $60M5
Atalanta TherapeuticsAtalanta TherapeuticsBoston, MA, USRNA Therapiesest. 2018Atalanta TherapeuticsBoston, MA, US · est. 2018

Atalanta Therapeutics: A biotech pioneer in RNA interference-based treatments for neurodegenerative diseases.

Series A · $110M62
Adarx PharmaceuticalsAdarx PharmaceuticalsSan Diego, CA, USTherapeuticsest. 2019Adarx PharmaceuticalsSan Diego, CA, US · est. 2019

ADARx Pharmaceuticals: Pioneering in mRNA base editing for genetic medicine solutions.

Series C · $332M50
Icad
Icad
Public$59.5M1091984Nashua, NH, US
Board Member· Board

Leadership at Icad

Elliot SussmanElliot SussmanBoard Member
Mike KleinMike KleinBoard Member
Rakesh PatelRakesh PatelBoard Member
Thomas RuschThomas RuschFounder
Dana BrownDana BrownBoard Member
Susan WoodSusan WoodBoard Member
Freedom Meditech
Freedom Meditech
Series C$19.6M302006San Diego, CA, US
Board Member· Board

Leadership at Freedom Meditech

John BurdJohn BurdBoard Member
Craig MisrachCraig MisrachFounder
Keith IgnotzKeith IgnotzBoard Member
Mr. Craig H. MisrachMr. Craig H. MisrachBoard Member

Similar to Freedom Meditech

Free Flow MedicalFree Flow MedicalFremont, CA, USMedical Devicesest. 2017Free Flow MedicalFremont, CA, US · est. 2017

Free Flow Medical: Innovating next-gen devices for emphysema treatment to enhance patient life quality.

Series B · $4.9M30
Bioxytech RetinaBioxytech RetinaRichmond, CA, USMedical Devicesest. 2015Bioxytech RetinaRichmond, CA, US · est. 2015

Bioxytech Retina, founded in 2015, pioneers non-invasive optical devices for diabetes diagnosis.

Pre-Seed · $1.2M5
Channel MedsystemsChannel MedsystemsSan Francisco, CA, USMedical Devicesest. 2009Channel MedsystemsSan Francisco, CA, US · est. 2009

San Francisco-based Channel Medsystems develops and delivers non-invasive medical technology products.

Series A · $62.9M35
Noninvasive Medical TechnologiesNoninvasive Medical TechnologiesLas Vegas, NV, USMedical Devicesest. 2006Noninvasive Medical TechnologiesLas Vegas, NV, US · est. 2006

NMT: Innovating noninvasive hemodynamic monitoring tools for enhanced medical care since 2003.

Series A · $6.3M11
Comhear
Comhear
Acquired$13.2M02013San Diego, CA, US
Board Member· Board

Leadership at Comhear

Randy GranovetterRandy GranovetterFounder
Gerry ChasteletGerry ChasteletCEO
andrew arnoandrew arnoBoard Member
Robert D KutnickRobert D KutnickBoard Member

Similar to Comhear

EvenEvenNew York City, NY, USHearing Productsest. 2014EvenNew York City, NY, US · est. 2014

Even designs and markets adaptive technology products tailored to individual hearing needs.

Seed · $2M15
SonicalSonicalSan Mateo, CA, USAudio Softwareest. 2023SonicalSan Mateo, CA, US · est. 2023

Sonical: Personalizing your audio experience with AI and advanced processing.

Seed · $3.9M6
inspEarinspEarMiami Lakes, FL, USWearable Devicesest. 2012inspEarMiami Lakes, FL, US · est. 2012

inspEar, an Arta Group start-up, revolutionizes the hearable market with multifunctional, custom-fitted earbuds.

Seed · $300k7
AudibilityAudibilityPortland, OR, USHeadphonesest. 2015AudibilityPortland, OR, US · est. 2015

Tech-advanced, socially-minded Audibility provides custom audio solutions for the deaf and hard of hearing.

Angel · $25k5
MD Revolution
MD Revolution

Solana Beach, CA, US

Board Member· Board

Andrew Sassine's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Andrew Sassine

Devin HorsmanDevin HorsmanCo-Founder · ArcturusKamal MistryKamal MistryCEO · Arcturus